Terufumi Kato

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer”.

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

New England Journal of Medicine(2023)10.1056/nejmoa2302983

N/A

7.3DataRank · unranked

1056 citations

Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi, Se‐Hoon Lee, Shugeng Gao +14 more

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology(2022)10.1200/jco.21.01308

N/A

7.3DataRank · unranked

1324 citations

Corinne Faivre‐Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz‐Ares +20 more

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2020.12.015

N/A

6.9DataRank · unranked

471 citations

David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste +18 more

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet(2024)10.1016/s0140-6736(24)01756-2

N/A

3.7DataRank · unranked

262 citations

Marina Chiara Garassino, Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, Masahiro Tsuboi +91 more

Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer

Clinical Lung Cancer(2022)10.1016/j.cllc.2022.04.005

N/A

0.489DataRank · unranked

14 citations

W. Victoria Lai, Raffaele Califano, Salma K. Jabbour, Charles M. Rudin, Corinne Faivre‐Finn +8 more

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management

Cancer Treatment Reviews(2022)10.1016/j.ctrv.2022.102378

N/A

0DataRank · unranked

170 citations

Mizuki Nishino, Lisa Lancaster, Bob T. Li, Andrew G. Nicholson, Brian J. Bartholmai +9 more